JP2014531465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531465A5 JP2014531465A5 JP2014533880A JP2014533880A JP2014531465A5 JP 2014531465 A5 JP2014531465 A5 JP 2014531465A5 JP 2014533880 A JP2014533880 A JP 2014533880A JP 2014533880 A JP2014533880 A JP 2014533880A JP 2014531465 A5 JP2014531465 A5 JP 2014531465A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- indazol
- pyrimidin
- methoxy
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GYPBSIFOIFDXKX-UHFFFAOYSA-N C=COCC1(CN)COC1 Chemical compound C=COCC1(CN)COC1 GYPBSIFOIFDXKX-UHFFFAOYSA-N 0.000 description 1
- 0 C[C@](*)(C=C(C)N(*)C(C)=C(C=NC(c1n[n]c2c1C=CC(C)(*)C=C2)=N)N)C=NC Chemical compound C[C@](*)(C=C(C)N(*)C(C)=C(C=NC(c1n[n]c2c1C=CC(C)(*)C=C2)=N)N)C=NC 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11184061 | 2011-10-06 | ||
| EP11184061.7 | 2011-10-06 | ||
| PCT/EP2012/069562 WO2013050438A1 (en) | 2011-10-06 | 2012-10-04 | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531465A JP2014531465A (ja) | 2014-11-27 |
| JP2014531465A5 true JP2014531465A5 (enExample) | 2016-01-14 |
| JP6140170B2 JP6140170B2 (ja) | 2017-05-31 |
Family
ID=46968229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533880A Expired - Fee Related JP6140170B2 (ja) | 2011-10-06 | 2012-10-04 | 過増殖性疾患の処置におけるｂｕｂ１キナーゼ阻害剤として使用するための置換ベンジルインダゾール類 |
Country Status (38)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
| HK1207861A1 (en) * | 2012-05-11 | 2016-02-12 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| HK1223350A1 (zh) * | 2013-03-21 | 2017-07-28 | Bayer Pharma Aktiengesellschaft | 杂芳基取代的吲唑 |
| US20160052912A1 (en) * | 2013-03-21 | 2016-02-25 | Bayer Pharma Akitiengesellschaft | Diaminoheteroaryl substituted indazoles |
| US20160046610A1 (en) * | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CN105473570A (zh) * | 2013-06-21 | 2016-04-06 | 拜耳制药股份公司 | 二氨基杂芳基取代的吡唑 |
| EP3010904A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| WO2014202583A1 (en) * | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| EP3010911A1 (en) * | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| CN105452237A (zh) * | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| ES2708211T3 (es) * | 2014-06-17 | 2019-04-09 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas |
| CA2961578A1 (en) * | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| EP3194381A1 (en) * | 2014-09-19 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| JP2017530963A (ja) * | 2014-09-19 | 2017-10-19 | バイエル ファーマ アクチエンゲゼルシャフト | ベンジル置換インダゾール類 |
| MX2017003664A (es) * | 2014-09-19 | 2017-07-13 | Bayer Pharma AG | Indazoles sustituidos con benzilo como inhibidores de bub1. |
| GB201419264D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| AU2016212230B2 (en) | 2015-01-28 | 2019-09-19 | Bayer Pharma Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| HUE047988T2 (hu) * | 2015-06-09 | 2020-05-28 | Abbvie Inc | Nukleáris receptor modulátorok (ROR) gyulladásos és autoimmun betegségek kezelésére |
| US10227299B2 (en) | 2015-06-17 | 2019-03-12 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones |
| JP2019504826A (ja) * | 2015-12-16 | 2019-02-21 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| KR102048050B1 (ko) * | 2019-08-29 | 2020-01-22 | 대한민국 | Adb-푸비나카의 대사체 합성 방법 |
| CN110684016A (zh) * | 2019-09-27 | 2020-01-14 | 上海应用技术大学 | 一种含氟的azd9291衍生物及其制备方法和应用 |
| CA3196712A1 (en) | 2020-09-23 | 2022-03-31 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022072634A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| CN121712773A (zh) | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| EP4724151A1 (en) | 2023-06-08 | 2026-04-15 | Antares Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5470862A (en) | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
| DE59713007D1 (de) | 1996-10-14 | 2009-06-25 | Bayer Healthcare Ag | Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19846514A1 (de) * | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| ES2295441T3 (es) | 2001-12-18 | 2008-04-16 | MERCK & CO., INC. | Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato. |
| US7166293B2 (en) | 2002-03-29 | 2007-01-23 | Carlsbad Technology, Inc. | Angiogenesis inhibitors |
| HK1077762A1 (zh) | 2002-09-10 | 2006-02-24 | Scios Inc. | TFGß[转化生长因子]的抑制剂 |
| DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| WO2007038613A2 (en) | 2005-09-26 | 2007-04-05 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
| CA2553513A1 (en) | 2004-01-22 | 2005-08-04 | Altana Pharma Ag | N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors |
| WO2007065010A2 (en) * | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| EP2148877A2 (en) | 2007-05-18 | 2010-02-03 | Bayer Schering Pharma AG | Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| ES2630026T3 (es) | 2008-12-18 | 2017-08-17 | Nerviano Medical Sciences S.R.L. | Derivados indazólicos sustituidos activos como inhibidores de cinasa |
| US20120232062A1 (en) | 2009-10-20 | 2012-09-13 | Eiger Biopharmaceuticals, Inc. | Azaindazoles to treat flaviviridae virus infection |
| PL2604608T3 (pl) | 2009-11-27 | 2016-02-29 | Adverio Pharma Gmbh | Sposób wytwarzania {4,6-diamino-2-[1-(2-fluorobenzylo)-1H-pirazolo[3,4-b]pirydyn-3-ylo]pirymidyn-5-ylo}metylokarbaminianu metylu |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| WO2012003405A1 (en) | 2010-06-30 | 2012-01-05 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
| CN104066731B (zh) | 2011-12-27 | 2016-06-15 | 铁木医药有限公司 | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 |
| HK1207861A1 (en) | 2012-05-11 | 2016-02-12 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| US9487508B2 (en) | 2012-09-19 | 2016-11-08 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| WO2014047662A2 (en) | 2012-09-24 | 2014-03-27 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| US20160046610A1 (en) | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| US20160052912A1 (en) | 2013-03-21 | 2016-02-25 | Bayer Pharma Akitiengesellschaft | Diaminoheteroaryl substituted indazoles |
| HK1223350A1 (zh) | 2013-03-21 | 2017-07-28 | Bayer Pharma Aktiengesellschaft | 杂芳基取代的吲唑 |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| CN105473570A (zh) | 2013-06-21 | 2016-04-06 | 拜耳制药股份公司 | 二氨基杂芳基取代的吡唑 |
| EP3010904A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| EP3010911A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| WO2014202583A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| EP3194381A1 (en) | 2014-09-19 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| JP2017530963A (ja) | 2014-09-19 | 2017-10-19 | バイエル ファーマ アクチエンゲゼルシャフト | ベンジル置換インダゾール類 |
| MX2017003664A (es) | 2014-09-19 | 2017-07-13 | Bayer Pharma AG | Indazoles sustituidos con benzilo como inhibidores de bub1. |
| CA2961578A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
-
2012
- 2012-04-10 UA UAA201404803A patent/UA111754C2/uk unknown
- 2012-10-04 ES ES12766997.6T patent/ES2665036T3/es active Active
- 2012-10-04 AP AP2014007533A patent/AP3847A/en active
- 2012-10-04 WO PCT/EP2012/069562 patent/WO2013050438A1/en not_active Ceased
- 2012-10-04 HU HUE12766997A patent/HUE037154T2/hu unknown
- 2012-10-04 PH PH1/2014/500758A patent/PH12014500758A1/en unknown
- 2012-10-04 US US14/350,160 patent/US20140249133A1/en active Granted
- 2012-10-04 NO NO12766997A patent/NO2763982T3/no unknown
- 2012-10-04 PL PL12766997T patent/PL2763982T3/pl unknown
- 2012-10-04 EA EA201400412A patent/EA201400412A1/ru unknown
- 2012-10-04 CA CA2851037A patent/CA2851037A1/en not_active Abandoned
- 2012-10-04 DK DK12766997.6T patent/DK2763982T3/en active
- 2012-10-04 CN CN201280059851.2A patent/CN103974948B/zh not_active Expired - Fee Related
- 2012-10-04 EP EP12766997.6A patent/EP2763982B1/en active Active
- 2012-10-04 KR KR1020147011914A patent/KR102007056B1/ko not_active Expired - Fee Related
- 2012-10-04 SG SG11201400616YA patent/SG11201400616YA/en unknown
- 2012-10-04 SI SI201231274T patent/SI2763982T1/en unknown
- 2012-10-04 AU AU2012320582A patent/AU2012320582B2/en not_active Ceased
- 2012-10-04 RS RS20180403A patent/RS57099B1/sr unknown
- 2012-10-04 BR BR112014008045A patent/BR112014008045A2/pt not_active Application Discontinuation
- 2012-10-04 JP JP2014533880A patent/JP6140170B2/ja not_active Expired - Fee Related
- 2012-10-04 HR HRP20180546TT patent/HRP20180546T1/hr unknown
- 2012-10-04 PT PT127669976T patent/PT2763982T/pt unknown
- 2012-10-04 PE PE2014000471A patent/PE20141203A1/es active IP Right Grant
- 2012-10-04 MX MX2014004122A patent/MX361279B/es active IP Right Grant
- 2012-10-04 LT LTEP12766997.6T patent/LT2763982T/lt unknown
- 2012-10-05 AR ARP120103719A patent/AR088449A1/es unknown
- 2012-10-05 UY UY0001034374A patent/UY34374A/es not_active Application Discontinuation
- 2012-10-05 TW TW101137035A patent/TWI588141B/zh not_active IP Right Cessation
-
2014
- 2014-03-19 IL IL231591A patent/IL231591A/en active IP Right Grant
- 2014-04-04 CU CUP2014000043A patent/CU20140043A7/es unknown
- 2014-04-04 EC ECSP14013284 patent/ECSP14013284A/es unknown
- 2014-04-04 CO CO14073129A patent/CO6930363A2/es active IP Right Grant
- 2014-04-04 DO DO2014000062A patent/DOP2014000062A/es unknown
- 2014-04-04 CR CR20140161A patent/CR20140161A/es unknown
- 2014-04-04 TN TNP2014000138A patent/TN2014000138A1/en unknown
- 2014-04-04 GT GT201400063A patent/GT201400063A/es unknown
-
2017
- 2017-02-21 US US15/438,254 patent/US10266548B2/en not_active Expired - Fee Related
-
2018
- 2018-04-10 CY CY20181100391T patent/CY1120318T1/el unknown
-
2019
- 2019-03-21 US US16/360,811 patent/US10604532B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180546T1 (hr) | Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti | |
| US9855269B2 (en) | Aminoquinazoline and pyridopyrimidine derivatives | |
| US9670208B2 (en) | Serine/threonine kinase inhibitors | |
| US8901147B2 (en) | Bi-heteroaryl compounds as Vps34 inhibitors | |
| JP2017500364A5 (enExample) | ||
| KR102379517B1 (ko) | 세린/트레오닌 키나아제 억제제 | |
| JP6500010B2 (ja) | 新規ピリジン誘導体 | |
| SI3083586T1 (en) | The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products | |
| RU2014139601A (ru) | Ингибиторы серин/треониновых киназ | |
| CA2531619A1 (en) | Biaryl piperazinyl-pyridine analogues | |
| TW200536851A (en) | Compounds and methods of use | |
| JP2016514717A5 (enExample) | ||
| US20120041024A1 (en) | Quinolyl amines as kinase inhibitors | |
| JP2014518214A5 (enExample) | ||
| JP2016530299A5 (enExample) | ||
| JP2016523976A5 (enExample) | ||
| JP2016522231A5 (enExample) | ||
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| JP2011519891A5 (enExample) | ||
| RU2014132044A (ru) | Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars) | |
| JP2018508553A5 (enExample) | ||
| JP2019530708A5 (enExample) | ||
| KR20110006662A (ko) | 5-하이드록시피리미딘-4-카르복사미드 화합물 | |
| JP2022552160A5 (enExample) | ||
| JP2016505059A5 (enExample) |